The recurrence rate of simple internal carotid artery bifurcation aneurysms treated with endovascular therapy was 13.6%.
Background:
Coagulopathy is an important factor causing progression of intracranial hemorrhage (ICH) after traumatic brain injury (TBI) and subsequently determining disability and mortality. Laboratory tests, including international normalized ratio (INR), partial thromboplastin time (PTT), and platelet count (PC) can be used to assess coagulopathy. Objective: To determine the predictive value of coagulopathy on ICH, need for neurosurgical intervention, and mortality. Design: Single institution retrospective cohort study. Methods: Patients with isolated blunt TBI progression of ICH evaluated with INR, PTT, and PC were analyzed, excluding those treated pre-morbidly with anticoagulation and antiplatelet agents. Isolated TBI was defined as a head Abbreviated Injury Scale (AIS) score ≥3 and other body region AIS score <3. Initial and follow-up (8 hours later) head CT scans were reviewed for skull fracture and ICH -epidural hemorrhage (EDH), subdural hemorrhage (SDH), subarachnoid hemorrhage (SAH), intraparenchymal hemorrhage (IPH), and intraventricular hemorrhage (IVH). Coagulopathy was defined as INR ≥1.5, PTT ≥35 seconds, or PC ≤100,000. Coagulopathic patients were compared to those without coagulopathy for outcome measure of ICH progression and mortality. ICH size was determined by measuring the largest diameter in the axial plane, and progression was defined as increase in size of ICH or new ICH on follow-up head CT. Neurosurgical intervention was defined as craniotomy or craniectomy. Results: A total of 3608 patients had TBI, 1398 had ICH on initial head CT. Of the patients with ICH, 804 had isolated TBI, and of those, 591 (mean age, 46.8 years, 67% male) met inclusion criteria. A fall was the most common mechanism of injury (40%); 13.4% were coagulopathic, 3.6% had low PC, 6.6% had elevated INR, and 8.0% had elevated PTT. Coagulopathic patients had lower Glasgow Coma Scale score (12 vs 15), but AIS was similar. SAH (54%) and SDH (49.4%) were most common. Twenty-two percent had ICH progression; coagulopathy was more common with progression (39.3% vs 19.2%). Progression of ICH was associated with low PC and elevated INR but not with elevated PTT. Overall, 4.4% required neurosurgical intervention, and low PC was a positive predictor. The mortality rate was 13.2%, and low PC was a positive predictor for death. Conclusions: Coagulopathy, particularly low PC, is a predictor of ICH progression, need for neurosurgical intervention, and mortality for patients with TBI. Reviewer's Comments: This study emphasizes an important observation of which most neurosurgeons are aware, which is that coagulopathy is an important determinant of increased need for neurosurgical intervention and poor outcome. This study does not evaluate the additional impact of anticoagulant and antiplatelet agents, which also are associated with ICH progression and poorer outcome. The authors acknowledge that they did not include thromboelastography (TEG) in determining coagulopathy. This test, which is becoming more widely available, can assess overall coagulation status, including platelet dysfunction. I suspect TEG will supplant these other tests in the future. (Reviewer-N. Scott Litofsky, MD, FACS).
New Oral Anticoagulants
How I Treat: Target Specific Oral Anticoagulant Associated Bleeding. Background: While vitamin K and coagulation factor replacement (fresh frozen plasma [FFP] or prothrombin complex concentrates [PCCs] , or VIIa) is the standard to reverse warfarin, there is no therapy agreed upon to reverse the direct acting anticoagulants. Furthermore, most hospitals lack tests to determine the degree of anticoagulation in patients taking these drugs. The international normalized ratio (INR) and the prothromboplastin time (PTT) can be normal despite an adequate anticoagulation. Objective: To review treatment options for bleedings associated with the direct acting anticoagulants. Design: Retrospective. Methods: Literature review. Results: Currently, the best test for evaluating the degree of anticoagulation with dabigatran is the hemoclot assay, which measures thrombin inhibition. Xa activity, in turn, is the best way to evaluate patients taking rivaroxaban and apixaban. When assessing these patients, one has to remember that these new anticoagulants take about 12 hours to clear unless renal function is altered, especially with dabigatran, which is essentially cleared by the kidney. You also need to know that the plasma levels of direct-acting anticoagulants are increased by P-glycoprotein such as amiodarone, verapamil, quinine, and clarithromycin. Plasma levels are also increased by grapefruit juice, antimycotics, and HIV protease inhibitors. A proposed algorithm to treat patients with life-threatening bleeding is as follows: patients taking dabigatran are currently best treated with prothrombin complex concentrates (PCCs), while those taking rivaroxaban and apixaban are best treated with 4-factor activated PCCs. Hemodialysis is also prescribed for dabigatran removal. Finally, charcoal hemoperfusion, desmopressin, and antifibrinolytic can be ordered. There is no evidence that FFP or VIIa are of any use. Conclusions: There are no accepted guidelines on how to treat acute intracranial bleeding in patients taking direct-acting anticoagulants. Reviewer's Comments: Antidotes are urgently needed if we are to treat these patients appropriately. And that is about to happen. A humanized monoclonal antibody fragment against dabigatran is now being tested clinically and a decoy inactive Xa will be used to reverse the effect of rivaroxaban and apixaban. (ReviewerLuc Jasmin, MD, PhD, FRCS (C), FACS, FAANS).
